Status: Recruiting
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.
Participants needed: 45
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.Updated: Sep 29, 2025Locations: 3
Eligibility criteria
Diagnosis of diabetes mellitus (type 1 or type 2) according to ADA or WHO diabet... [+6]
Subjects with unstable metabolic or blood pressure control [+4]